Aptus Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE15XJ01010
  • NSEID:
  • BSEID: 544529
INR
214.45
10.2 (4.99%)
BSENSE

Jun 03, 03:30 PM

BSE+NSE Vol: 7200

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

7.2 k (-47.52%) Volume

Shareholding (May 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

72.89%

What is the bonus history of Aptus Pharma?

30-Apr-2026

Aptus Pharma recently announced a 3:2 bonus issue, with an ex-date of May 12, 2026. Shareholders on record by this date will receive 3 additional shares for every 2 shares they currently hold.

Aptus Pharma has a recent bonus issue where they announced a 3:2 bonus. The ex-date for this bonus is set for May 12, 2026. This means that shareholders on record as of this date will receive additional shares in the ratio of 3 shares for every 2 shares they currently hold.

View full answer

Why is Aptus Pharma Ltd falling/rising?

03-Jun-2026

As of 02-Jun, Aptus Pharma Ltd's stock price is rising to Rs. 204.25, reflecting a 4.99% increase. This growth is driven by strong recent performance, including a 201.25% year-to-date surge, despite a decline in investor participation.

As of 02-Jun, Aptus Pharma Ltd's stock price is rising, currently at Rs. 204.25, reflecting a change of 9.7 (4.99%) upward. This increase is supported by several factors. The stock has shown strong performance over the past week, gaining 14.75%, while the benchmark Sensex has declined by 1.79%. Over the past month, Aptus Pharma has risen by 26.08%, contrasting with a 2.94% drop in the Sensex. Year-to-date, the stock has surged by an impressive 201.25%, while the Sensex has fallen by 12.40%.<BR><BR>Today, the stock reached a new 52-week high of Rs. 204.25 and has outperformed its sector by 5.67%. It has been on a consecutive gain streak for the last three days, accumulating a total return of 15.72% during this period. The stock opened with a gain of 4.99% today and has maintained this price level throughout the trading session.<BR><BR>Additionally, Aptus Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 41.54% compared to the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading.<BR><BR>Overall, the combination of strong recent performance, reaching new highs, and consistent gains contributes to the rising stock price of Aptus Pharma Ltd.

View full answer

Which are the latest news on Aptus Pharma?

03-Jun-2026

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 368 Cr (Micro Cap)

stock-summary
P/E

80.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

21.29%

stock-summary
Price to Book

16.14

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
101.13%
0%
101.13%
6 Months
244.0%
0%
244.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Aptus Pharma for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Investor Presentation

29-May-2026 | Source : BSE

Announcement Under Regulation 30 (LODR): Investor Presentation

Brand Promotion Initiative At Rajkot Hirasar Airport

22-May-2026 | Source : BSE

Intimation under Regulation 30 of SEBI (LODR) Regulations 2015: Brand Promotion Initiative at Rajkot Hirasar Airport

Disclosure As Per Regulation 7(2) Of SEBI (PIT) Regulations 2015

15-May-2026 | Source : BSE

Disclosure as per Regulation 7 (2) of SEBI (PIT) Regulations 2015

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

Aptus Pharma Ltd has announced 3:2 bonus issue, ex-date: 12 May 26

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
4.28
Debt to EBITDA (avg)
1.71
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.82
Tax Ratio
27.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.87%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
80
Industry P/E
33
Price to Book Value
16.95
EV to EBIT
51.44
EV to EBITDA
48.61
EV to Capital Employed
23.26
EV to Sales
7.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
45.21%
ROE (Latest)
21.29%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
RSI
Bearish
Bollinger Bands
Bullish
KST
Dow Theory
Bullish
Bullish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : May 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Kapilbhai Hasmukhbhai Chandarana (0.11%)

Highest Public shareholder

None

Individual Investors Holdings

23.76%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Aptus Pharma"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2026 is 123.92% vs 47.34% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Mar 2026 is 64.00% vs 33.59% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.20",
          "val2": "14.38",
          "chgp": "123.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.50",
          "val2": "2.93",
          "chgp": "53.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.35",
          "val2": "0.43",
          "chgp": "-18.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.87",
          "val2": "1.75",
          "chgp": "64.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "13.98%",
          "val2": "20.38%",
          "chgp": "-6.40%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Aptus Pharma"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 89.62% vs 37.51% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 56.08% vs 270.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "46.57",
          "val2": "24.56",
          "chgp": "89.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.44",
          "val2": "4.75",
          "chgp": "56.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.47",
          "chgp": "70.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.62",
          "val2": "2.96",
          "chgp": "56.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.98%",
          "val2": "19.34%",
          "chgp": "-3.36%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Half Yearly Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Sep'25
Change(%)
Net Sales
32.20
14.38
123.92%
Operating Profit (PBDIT) excl Other Income
4.50
2.93
53.58%
Interest
0.35
0.43
-18.60%
Exceptional Items
0.00
0.00
Standalone Net Profit
2.87
1.75
64.00%
Operating Profit Margin (Excl OI)
13.98%
20.38%
-6.40%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Mar 2026 is 123.92% vs 47.34% in Sep 2025

Direction Arrows
Standalone Net Profit

Growth in half year ended Mar 2026 is 64.00% vs 33.59% in Sep 2025

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
46.57
24.56
89.62%
Operating Profit (PBDIT) excl Other Income
7.44
4.75
56.63%
Interest
0.80
0.47
70.21%
Exceptional Items
0.00
0.00
Standalone Net Profit
4.62
2.96
56.08%
Operating Profit Margin (Excl OI)
15.98%
19.34%
-3.36%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 89.62% vs 37.51% in Mar 2025

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2026 is 56.08% vs 270.00% in Mar 2025

stock-summaryCompany CV
About Aptus Pharma Ltd stock-summary
stock-summary
Aptus Pharma Ltd
Micro Cap
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available